Flt3 flk 2 c 20 sc 479

Manufactured by Santa Cruz Biotechnology

FLT3/Flk-2 (C-20) (sc-479) is an antibody product offered by Santa Cruz Biotechnology. It is a polyclonal antibody raised against a peptide mapping at the C-terminus of FLT3/Flk-2 of human origin.

Automatically generated - may contain errors

Lab products found in correlation

Total akt, by Cell Signaling Technology (2 mentions) β tubulin, by Santa Cruz Biotechnology (2 mentions) Ubiquitin p4d1 sc 8017, by Santa Cruz Biotechnology (1 mentions) Anti gapdh 14c10, by Santa Cruz Biotechnology (1 mentions) Ab4080, by Abcam (1 mentions) Anti ubiquitin antibody, by Abcam (1 mentions) Ab7780, by Abcam (1 mentions) Ub p4d1, by Santa Cruz Biotechnology (1 mentions) Phospho kit tyr719, by Cell Signaling Technology (1 mentions) Anti gapdh 14c10, by Cell Signaling Technology (1 mentions) Phospho kit tyr703, by Cell Signaling Technology (1 mentions)

4 protocols using flt3 flk 2 c 20 sc 479

Immunoblotting Antibody Validation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following antibodies were purchased from Cell Signaling Technology (Danvers, MA): total AKT (rabbit, #9272) and total p44/42 MAPK (Erk1/2) (3A7) (mouse, #9107) were used at 1:1000. Anti-GAPDH (D16H-11) XP (R) (rabbit mAb, #5174) was used at 1:1000. Phospho-AKT (Ser 473) (D9E) XP(R) (rabbit mAb, #4060) was used at 1:1000. Phospho-p44/42 MAPK (T202/Y204) (rabbit, #9101) was used at 1:1000. Phospho-S6 ribosomal protein (S235/236) (D57.2.2E) XP (R) (rabbit mAb, #4858) was used at 1:1000. Total S6 ribosomal protein (SG10) (rabbit mAb, #2217) was used at 1:1000. Phospho-STAT5 Tyr694 (rabbit, #9351S) and total STAT5 (3H7) (rabbit, #9358 mAb) were used at 1:1000. The Syk (D3Z1E) XP (rabbit mAb, #13198) was used at 1:1000.
FLT3/Flk-2 (C-20) (sc-479) was purchased from Santa Cruz Biotechnology, Inc., (Dallas, TX) and used at 1:1000 for immunoblotting. Anti-pTyr (mouse, clone 4G10) was purchased from Upstate Biotechnology (Lake Placid, NY) and was used at 1:1000 in the presence of 4% BSA.

Weisberg E.L., Puissant A., Stone R., Sattler M., Buhrlage S.J., Yang J., Manley P.W., Meng C., Buonopane M., Daley J.F., Lazo S., Wright R., Weinstock D.M., Christie A.L., Stegmaier K, & Griffin J.D. (2017). Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget, 8(32), 52026-52044.

+ Open protocol

+ Expand

Immunoblotting Antibody Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following antibodies were purchased from Cell Signaling Technology (Danvers, MA): AKT (rabbit, #9272), p44/42 MAPK (Erk1/2) (3A7) (mouse, #9107), Syk (D3Z1E) XP (rabbit mAb, #13198), beta-tubulin (rabbit, #2146), USP10 (D7A5) (rabbit mAb, #8501) and FES (rabbit, #2736) were used at 1:1000 for immunoblotting, and anti-GAPDH (14C10) (rabbit mAb, #2118) was used at 1:3000.
Flt-3/Flk-2 (C-20) (sc-479) and ubiquitin (P4D1) (sc-8017) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX) and used at 1:1000 for immunoblotting. Anti-pTyr (mouse, clone 4G10) was purchased from MilliporeSigma (Burlington, MA) and was used at 1:1000 for immunoblotting in the presence of 4% BSA. Anti-HAUSP/USP7 antibody (ab4080) was purchased from Abcam (Cambridge, MA) and used at 1:1000 for immunoblotting.

Yang J., Meng C., Weisberg E., Case A., Lamberto I., Magin R.S., Adamia S., Wang J., Gray N., Liu S., Stone R., Sattler M., Buhrlage S, & Griffin J.D. (2020). Inhibition of the deubiquitinase USP10 induces degradation of SYK. British Journal of Cancer, 122(8), 1175-1184.

+ Open protocol

+ Expand

Western Blot Antibody Optimizations

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following antibodies were purchased from Cell Signaling Technology (Danvers, MA): total AKT (rabbit, #9272) and total p44/42 MAPK (Erk1/2) (3A7) (mouse, #9107) were used at 1:1000. Anti-GAPDH (D16H-11) XP (R) (rabbit mAb, #5174) was used at 1:1000. Beclin-1 (rabbit, #3738) was used at 1:1000. USP10 (D7A5) (rabbit, #8501) was used at 1:1000. P53 (rabbit, #9282) was used at 1:1000. β-tubulin (rabbit, #2146s) was used 1:1000.
FLT3/Flk-2 (C-20) (sc-479) and Ub (P4D1) (mouse, sc-8017) were purchased from Santa Cruz Biotechnology, Inc., (Dallas, TX) and used at 1:1000 for immunoblotting. Anti-pTyr (mouse, clone 4G10) was purchased from Upstate Biotechnology (Lake Placid, NY) was used at 1:1000. Anti-HAUSP/USP7 antibody (rabbit, ab4080) and anti-ubiquitin antibody (rabbit, ab7780) were purchased from Abcam (Cambridge, MA) and used at 1:1000.

Weisberg E.L., Schauer N.J., Yang J., Lamberto I., Doherty L., Bhatt S., Nonami A., Meng C., Letai A., Wright R., Tiv H., Gokhale P.C., Ritorto M.S., De Cesare V., Trost M., Christodoulou A., Christie A., Weinstock D.M., Adamia S., Stone R., Chauhan D., Anderson K.C., Seo H.S., Dhe-Paganon S., Sattler M., Gray N.S., Griffin J.D, & Buhrlage S.J. (2017). Inhibition of USP10 induces degradation of oncogenic FLT3. Nature chemical biology, 13(12), 1207-1215.

+ Open protocol

+ Expand

Western Blot Analysis of Tyrosine Kinases

Check if the same lab product or an alternative is used in the 5 most similar protocols

Anti-GAPDH (14C10) (rabbit mAb, #2118) (Cell Signaling Technology (Danvers, MA)) was used at a dilution of 1:3000. Also purchased from Cell Signaling Technology were phospho-KIT (Tyr719) (rabbit Ab, #3391), phospho-KIT (Tyr703) (rabbit Ab, #3073), KIT (D13A2) XP (rabbit mAb, #3074), and phospho-FLT3 (Tyr591) (54H1) (mouse mAb, #3466); each was used at a dilution of 1:1000. FLT3/Flk-2 (C-20) (sc-479) (Santa Cruz Biotechnology, Inc. (Dallas, TX)) was used at a dilution of 1:1000, and p-TYR (4G10), #05-321 (MilliporeSigma (Burlington, MA)) was used at a dilution of 1:1000.

Weisberg E., Meng C., Case A., Sattler M., Tiv H.L., Gokhale P.C., Buhrlage S., Liu X., Yang J., Wang J., Gray N., Stone R., Adamia S., Dubreuil P., Letard S, & Griffin J.D. (2019). Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT and FLT3 in hematologic malignancies: Mutant KIT and FLT3 response to Tyrosine Kinase Inhibitors. British journal of haematology, 187(4), 488-501.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!